AtriCure, Inc. (ATRC)

Over the past six months, AtriCure's stock experienced an overall decline, reaching a new 52-week low. In Q1 2026, AtriCure reported revenue of $141.25 million, up 14.3% year-over-year, surpassing analyst expectations, and reported $0.00 EPS, beating analysts' consensus estimates. AtriCure reported its fourth-quarter and full-year 2025 financial results around February 17, 2026. Analyst sentiment remains mostly constructive, with a "Moderate Buy" consensus rating. An insider, Vinayak Doraiswamy, sold 5,000 shares of the stock. AtriCure participated in the Citizens Life Sciences Conference in February 2026 and was scheduled to participate in the 2026 Bank of America Securities Health Care Conference in May 2026.

The provided information does not explicitly detail the demand seasonality for AtriCure, Inc.'s products and services. However, the company's revenue is reported by product categories and by geographic regions, which could be influenced by factors such as healthcare spending cycles, surgical scheduling patterns, and new product launches. The company projects continued growth with revenue forecasts for upcoming quarters, indicating sustained demand for its products.

AtriCure, Inc. is a medical device company focused on developing therapies for atrial fibrillation (AFib), left atrial appendage (LAA) management, and post-operative pain management. Their product portfolio includes the Isolator® Synergy™ Ablation System, AtriClip® Left Atrial Appendage Exclusion System, Hybrid AF™ Therapy, and Cryoablation Systems. The Isolator® Synergy™ Ablation System delivers controlled radiofrequency energy to create ablation lesions. The AtriClip® Left Atrial Appendage Exclusion System is designed to close the left atrial appendage to reduce the risk of stroke. Hybrid AF™ Therapy combines surgical and catheter-based approaches. Cryoablation Systems offer an alternative ablation modality using freezing techniques. The company also offers multifunctional pens, linear ablation devices, access devices, and minimally invasive surgical instruments.

AtriCure operates internationally with sales and distribution channels across North America, Europe, Asia, and select emerging markets. While a majority of its revenue is generated from the United States, the company also has a significant international presence. AtriCure's corporate headquarters are located near Cincinnati, Ohio, with additional offices in Minneapolis, Minnesota, Pleasanton, California, and Amsterdam, Netherlands, which serves as the headquarters for AtriCure Europe BV.

AtriCure maintains a strong brand reputation within the medical device industry, particularly for its leadership in surgical ablation devices for atrial fibrillation. The company's strong Q1 2026 financial results positively reinforced its reputation. Continued investment in R&D demonstrates its commitment to advancing the standard of care. Strategic partnerships and acquisitions further solidify its market position. AtriCure is committed to environmental, social, and governance responsibilities, contributing to a positive brand image. Emerging competition from new technologies like Pulsed Field Ablation (PFA) could impact the company's reputation.

AtriCure's ownership is largely dominated by institutional investors, who collectively held approximately 81.46% of the company's stock as of mid-2025. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Wellington Management Group Llp. Insiders represent a smaller portion of ownership, at approximately 3.55% as of mid-2025 and 3.96% according to other data. Public companies and individual investors account for the remaining portion.